Floatz logo

18f-flt

Male Breast Carcinoma

University of WashingtonSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Male Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Irvine
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB

View all 50 →

Same molecule, other indications

18f-flt is also rated in:

acute lymphoblastic leukemiaDormant
B
Indicative ·
62 / 100
View asset →
breast carcinomaDormant
B
Indicative ·
58 / 100
View asset →
Stage IIB Breast CancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →